Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

Titre officiel

A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients >= 60 Receiving Cytotoxic Chemotherapy

Sommaire:

On entend par « CHIP » l’hématopoïèse clonale de signification indéterminée, c’est-à-dire les mutations des cellules souches de la moelle osseuse qui donnent à cette population de cellules un avantage de survie ou « clonal » sur le plan de la croissance. Cette étude vise à déterminer si la CHIP chez les patients atteints d’un lymphome âgés de 60 ans et plus est un facteur de risque de complications liées à la chimiothérapie, comme les numérations globulaires basses, les infections, les effets cardiaques, les hospitalisations, les retards et les réductions de dose, et l’incapacité à revenir à une numération globulaire normale après la fin de la chimiothérapie.

Description de l'essai

Primary Outcome:

  • Determine if CHIP is an independent risk factor for chemotherapy-induced complications.
  • Emerging dysmyelopoiesis after chemotherapy
Secondary Outcome:
  • Expansion of clonal hematopoietic stem cells
  • Development of therapy-related myeloid neoplasm
  • Overall survival
'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance (1-4). Up to 20% of individuals in the general population acquire mutations in their bone marrow stem cells as they age that give that population of cells a survival or 'clonal' advantage for growth. The frequency of CHIP may be higher in patients with other cancers. CHIP increases with age, and has been shown to be a risk factor associated with cardiovascular disease and a tendency to the development of bone marrow cancers at a rate of 1% per year (1,2,5). CHIP is also associated with the development of bone marrow cancers that occur after chemotherapy. The investigators want to investigate whether CHIP is also a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions. They are also interested in determining if CHIP may explain why some patients do not recover normal blood counts after chemotherapy finishes. The results from this study may help physicians better understand why some people have difficulty with chemotherapy (in the short and long-term) while others do not. Screening for CHIP in older patients may become a recommended standard that allows physicians to tailor anti-cancer treatment to the patient.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer